Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/CorMedix Inc./ 10-Q

Quarterly Report · 10-Q

CorMedix Inc.

CRMDNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2024Accepted Aug 14, 2024, 8:15 AM EDTCIK 1410098Accession 0001213900-24-068600
View company →Permanent SEC source ↗
Share

Company context

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Current securities

CRMDNASDAQ · EQUITY · Current
Historical securities (1)
CRMD.WSNYSE_AMERICAN · WARRANT · Historical · closed Apr 30, 2015

Recent company filings

  1. Results of Operations and Financial Condition · Regulation FD DisclosureNov 2, 2026
  2. Regulation FD DisclosureOct 19, 2026
  3. 10-Q filingAug 13, 2026
  4. Results of Operations and Financial ConditionAug 13, 2026
  5. Other EventsAug 7, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.